Alex joined Oxford Science Enterprises in October 2019, bringing over two decades of clinical medicine and corporate finance experience.
Alex is responsible for major corporate finance activities at OSE and its later stage companies, including public market transactions, acquisitions and exits. He also manages OSE’s Investment Committee, and leads long-term strategic planning.
Alex began his career as a junior doctor in Oxford before joining investment banking in 2007. He has raised equity and debt capital for both private and public companies, and advised on local and cross-border M&A and partnerships whilst at UBS and Lazard in Europe, US and Australia-Pacific. His experience includes both large cap pharma and medtech, early-stage biotech and digital health, as well as cleantech, utilities and infrastructure.
Alex holds degrees in medicine & surgery and physiological sciences from the University of Oxford.
